Multivariate analysis of the association between oocyte donor characteristics, including basal follicle stimulating hormone (FSH) and age, and IVF cycle outcomes.
OBJECTIVE
To determine whether oocyte donor FSH and age are independently associated IVF cycle success.


METHODS
Retrospective cohort study.


METHODS
University hospital-based IVF clinic.


METHODS
Three hundred twelve donor/recipient pairs undergoing oocyte donation IVF.


METHODS
Number of mature oocytes and embryos, clinical pregnancy, and live birth rates.


RESULTS
Donors' basal FSH levels were not associated with IVF cycle outcomes. However, for every year increase in donor age, the number of mature oocytes decreased by 0.39 and the number of embryos decreased by 0.25 resulting in 1 less embryo for each 4-year increase in age, even in young donors. For every 100 pg/mL increase in estradiol on the day of hCG administration, the number of mature oocytes increased by 0.49 and the number of embryos increased by 0.36. For each additional 75 IU of gonadotropin used during stimulation, the likelihood of pregnancy and live birth decreased by 3.5%.


CONCLUSIONS
Donor oocyte IVF cycle outcomes were not associated with donor basal FSH. However, donor age and estradiol level on the day of hCG administration were significantly associated with numbers of mature oocytes and embryos obtained, and the amount of gonadotropin used in the stimulation was significantly associated with the likelihood of pregnancy and live birth.
Barton
Sara E
SE
Division of Reproductive Medicine, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: sbarton@partners.org.
Missmer
Stacey A
SA
Division of Reproductive Medicine, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts; Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts.
Ashby
Rachel K
RK
Division of Reproductive Medicine, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Ginsburg
Elizabeth S
ES
Division of Reproductive Medicine, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
D000328:Adult; D000367:Age Factors; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D015999:Multivariate Analysis; D018587:Oocyte Donation / Q000379:methods; D010060:Ovulation / Q000097:blood; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D018873:Pregnancy Rate; D014019:Tissue Donors; D016896:Treatment Outcome; D055815:Young Adult
D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D004958:Estradiol; D005640:Follicle Stimulating Hormone